The study is intended to test the hypothesis that sodium lactate infusion after resuscitation from a cardiac arrest will decrease the magnitude of brain damage, as measured by the serum biomarker concentration of NSE.

开始日期2024-10-01

申办/合作机构

Hôpital Erasme

NCT06379815 / Not yet recruitingN/AIIT

Effect of Oral Lactate Ingestion on Appetite Regulation

The goal if this study is to determine how oral lactate ingestion affects markers of appetite regulation. Researchers will compare oral lactate ingestion to a sodium chloride placebo. Participants will consume the lactate or placebo solution and then have blood samples and assessments of appetite over the course of 90 min. Free-living energy intake will be measured for 3 days surrounding each experimental session.

开始日期2024-05-01

申办/合作机构

Wilfrid Laurier University

[+1]

NCT06110429 / Not yet recruiting临床3期IIT

Sodium Lactate Versus Hypertonic Saline Solution in the Treatment of Intracranial Hypertensive Episodes in Severe Brain Injured Patients

Brain oedema is a major complication of brain injury (TBI). It increases the risk of intracranial hypertension (ICH) and brain hypoxia, leading to an increase in mortality and poor neurologic outcome. Increased water content in the injured brain can be related to a vasogenic or cellular pathway. Osmotherapy, by using mannitol or hypertonic saline (HSS), is recommended and currently administered for the treatment of ICH in this setting. Beside these two usual treatments, sodium lactate (SL), a metabolic and neuroprotective solution, has recently been described as having similar effects on lowering intracranial pressure (ICP). In a previous study, conducted in patients with severe TBI, (1) Ichai et al. reported that a bolus of half-molar SL was as effective than equimolar doses of mannitol to reduce elevated ICP (less refractory ICH and higher and longer reduction of ICH).
Objective(s):
The purpose of the study is to analyze the effect on ICH of SL compared to a hypertonic saline solution (HSS).
Outcome(s):
The primary endpoint is the efficacy in lowering ICH after 4 h. Secondary endpoints were percentage of successfully treated episodes of intracranial hypertension and neurological status at discharge from ICU.

开始日期2024-01-01

申办/合作机构

Geneva University Hospital

100 项与乳酸钠相关的临床结果

登录后查看更多信息

100 项与乳酸钠相关的转化医学

登录后查看更多信息

100 项与乳酸钠相关的专利（医药）

登录后查看更多信息

697

项与乳酸钠相关的文献（医药）

2023-12-01·Neuropediatrics

Effects of Sodium Lactate Infusion in Two Girls with Glucose Transporter 1 Deficiency Syndrome

Article

作者: Wortmann, Saskia ; Willemsen, Michèl A ; van Alfen, Nens ; van Gemert, Loes A ; van Gaal, Lizzy

Abstract:

Background Glucose is an important fuel for the brain. In glucose transporter 1 deficiency syndrome (GLUT1DS), the transport of glucose across the blood–brain barrier is limited. Most individuals with GLUT1DS present with developmental problems, epilepsy, and (paroxysmal) movement disorders, and respond favorably to the ketogenic diet. Similar to ketones, lactate is an alternative energy source for the brain. The aim of this study is to investigate whether intravenous infusion of sodium lactate in children with GLUT1DS has beneficial effects on their epilepsy. Methods We performed a proof of principle study with two subjects with GLUT1DS who were not on a ketogenic diet and suffered from absence epilepsy. After overnight fasting, sodium lactate (600 mmol/L) was infused during 120 minutes, under video electroencephalographic (EEG) recording and monitoring of serum lactate, glucose, electrolytes, and pH. Furthermore, the EEGs were compared with pre-/postprandial EEGs of both subjects, obtained shortly before the study. Results Fasting EEGs of both subjects showed frequent bilateral, frontocentral polyspike and wave complexes. In one subject, no more epileptic discharges were seen postprandially and after the start of lactate infusion. The EEG of the other subject did not change, neither postprandially nor after lactate infusion. Serum pH, lactate, and sodium changed temporarily during the study. Conclusion This study suggests that sodium lactate infusion is possible in individuals with GLUT1DS, and may have potential therapeutic effects. Cellular abnormalities, beyond neuronal energy failure, may contribute to the underlying disease mechanisms of GLUT1DS, explaining why not all individuals respond to the supplementation of alternative energy sources.

2023-12-01·The American journal of clinical nutrition

Nutrient sensing: LEAP2 concentration in response to fasting, glucose, lactate, and β-hydroxybutyrate in healthy young males

Article

作者: Lauritzen, Esben Stistrup ; Støy, Julie ; Bjerre, Mette ; Pedersen, Mette Glavind Bülow ; Kampmann, Ulla ; Søndergaard, Esben ; Jessen, Niels ; Rittig, Nikolaj ; Møller, Niels ; Thomsen, Henrik Holm ; Svart, Mads Vandsted

BACKGROUND:

The appetite-suppressing potential of liver-expressed antimicrobial peptide 2 (LEAP2), and its antagonistic effects on the hunger-inducing hormone ghrelin have attracted scientific interest. It is unclear how LEAP2 is influenced by fasting and how it responds to specific nutrients.

OBJECTIVES:

The purpose of this investigation was to assess whether LEAP2 concentration 1) decreases after fasting, 2) increases postprandially, and 3) is regulated by nutrient sensing in the splanchnic bed.

METHODS:

Plasma LEAP2 concentration was measured in blood samples from 5 clinical cross-over trials, following 1) 36 h of fasting (n = 8), 2) 10 h of fasting (n = 37, baseline data pooled from 4 of the clinical trials), 3) Oral and intravenous glucose administration (n = 11), 4) Oral and intravenous Na-lactate administration (n = 10), and 5) Oral and intravenous Na-β-hydroxybutyrate (BHB) administration (n = 8). All 5 trials included healthy males.

RESULTS:

Compared with a 10-h fasting period, the median LEAP2 concentration was 38% lower following 36 h of fasting (P < 0.001). Oral administration of glucose elevated, whereas intravenous glucose administration lowered LEAP2 concentration (intervention x time, P = 0.001), resulting in a mean difference of 9 ng/mL (95% confidence interval [CI]: 1, 17) after 120 min. Oral lactate increased, and intravenous lactate decreased LEAP2 (intervention x time, P = 0.007), with a mean difference between interventions of 10 ng/mL (95% CI: 6, 15) after 120 min. In contrast, oral and intravenous administration of BHB reduced the LEAP2 concentration (main effect of time, P < 0.001).

CONCLUSIONS:

Our investigations show that LEAP2 concentration was lower after a 36-h fast than an overnight fast and that oral delivery of glucose and lactate elevated LEAP2 concentration compared with intravenous administration, whereas LEAP2 concentrations decreased with both oral and intravenous BHB. This indicates that the LEAP2 concentration is sensitive to intestinal exposure to specific substrates, highlighting the need for future studies exploring the relationship between nutrients and LEAP2. This trial was registered at clinicaltrials.gov as NCT01840098, NCT03204877, NCT04299815, NCT03935841, and NCT01705782.

2023-10-01·Food research international (Ottawa, Ont.)

Use of a compound modifier to retard the quality deterioration of frozen dough and its steamed bread

Article

作者: Wu, Hong ; Li, Bing ; Tan, Jin-Ming ; Han, Shuang-Yan

To retard the quality deterioration of the dough during frozen storage, the effects of a compound modifier (CM) comprised of sodium stearoyl lactate, VC, and β-glucanase on the properties of the frozen dough, as well as the quality of the frozen dough steamed bread were investigated. The results revealed that CM restricted the migration of water in the dough and improved its rheological properties. Furthermore, CM minimized the deterioration of specific volume and textural properties, and prevented starch retrogradation in the frozen dough steamed bread. Moreover, the addition of CM strengthened the secondary structure of gluten protein and formed a more resilient gluten network. The microstructure of the frozen dough steamed bread showed that CM reduced the damage caused by ice crystals on the gluten network. Overall, the use of CM strengthened the gluten network and effectively delayed the quality deterioration of the frozen dough, thus is potential as an improver for frozen dough.

项与乳酸钠相关的新闻（医药）

2024-04-23

·奇点网

《细胞》：难怪肿瘤偏爱“酸性体质”！苏州大学团队首次发现，瘤内乳酸会导致抑癌蛋白p53乳酸化，失去抗癌功能丨科学大发现

*仅供医学专业人士阅读参考众所周知，肿瘤嗜酸。它嗜酸到什么程度呢？这么说吧，即使在氧气充足的情况下，肿瘤也会启动糖酵解，生产大量的乳酸，把自己弄成“酸性体质”。很多人可能还不知道，我们剧烈运动之后身体产生的乳酸虽然让我们肌肉酸疼的乳酸，但肿瘤却把乳酸当做大宝贝。我们之前就介绍过肿瘤中乳酸的很多功能。例如，乳酸可以将瘤内的巨噬细胞从抗癌型变成促癌型，还可以增强调节性T细胞的免疫抑制功能，甚至还能导致PD-1抑制剂治疗失败。让我没想到的是，上面的研究成果竟然还不是瘤内乳酸的全部手段。今天，由苏州大学生物医学研究院周芳芳领衔的研究团队，在顶级期刊《细胞》上发表了一项重磅研究成果[1]。她们首次发现，肿瘤内的乳酸会被乳酸化酶AARS1识别，并添加到抑癌蛋白p53的DNA结合结构域的两个关键氨基酸上，导致抑癌蛋白p53因乳酸化而失活，最终促进癌症的进展。此外，她们还发现β-丙氨酸可以阻止AARS1对p53的乳酸化，为癌症的治疗提供了新思路。苏州大学的Zong Zhi和谢枫是论文的共同第一作者。据了解，这也是苏州大学首次以第一单位在《细胞》上发表研究成果[2]。论文首页截图正如文章开头说的那样，乳酸是促进肿瘤生长的重要代谢产物。虽然背后的机制已经有很多研究，但是乳酸与抑癌蛋白p53之间是否有关系，如果有的话，又是如何发生关系的，以及对肿瘤的发生发展有啥影响，目前仍知之甚少。周芳芳团队分析了癌症基因组图谱（TCGA）中的乳腺癌数据集，发现在p53正常的癌症患者中，血清乳酸水平高的患者，p53信号通路活跃程度较低。这似乎暗示，乳酸会抑制p53的功能。基于肿瘤小鼠模型的实验发现，给小鼠注射乳酸钠之后，小鼠成瘤更快，肿瘤的体积也更大；更重要的是，p53蛋白的活性确实也被抑制了。值得注意的是，将生成乳酸的乳酸脱氢酶A（LDHA）敲除后，会导致肿瘤形成延迟、肿瘤乳酸和肿瘤负荷减少，以及p53活性增加。以上研究结果说明，肿瘤产生的乳酸确实是抑癌蛋白p53的抑制剂。乳酸（盐）与肿瘤及p53之间的关系那乳酸是如何影响p53蛋白活性的呢？周芳芳团队先做了一个体外实验，发现用乳酸盐单独处理p53不会影响p53的活性；不过，一旦加入细胞裂解液之后，p53蛋白的活性就会受到乳酸盐的抑制，而且p53活性的降低，与p53的乳酸化水平增加有关。基于细胞的实验也证实了上述发现。因此，研究人员认为，乳酸可在细胞中被感知，并通过乳酸化成为p53的一部分，进而使p53失活。肯定有个什么机制用乳酸把p53乳酸化了接下来就是要找到乳酸化p53的关键酶了。周芳芳团队用CRISPR基因编辑技术，在全基因组范围内展开了地毯式筛查，丙氨酰-tRNA合成酶1（AARS1）很快浮出水面。在敲除AARS1后，肿瘤细胞在增殖、集落形成和异种移植肿瘤形成方面，均显著减弱。此外，AARS1缺失之后，乳酸钠促进肿瘤生长的能力也消失了。以上研究结果说明，AARS1是乳酸依赖性p53失活和肿瘤生长所必需的。AARS1现身随后，周芳芳团队揭示了AARS1乳酸化p53的机制。原来AARS1在识别到乳酸之后，会与乳酸结合，催化乳酸-AMP的形成，然后将乳酸转移到p53蛋白DNA结合结构域120（K120）和139（K139）号赖氨酸残基上，导致p53乳酸化，进而阻碍p53蛋白的液-液相分离（LLPS）、DNA结合和受调控基因的转录激活，最终达到抑制p53抑癌功能的效果。好消息是，周芳芳团队发现AARS1的底物β-丙氨酸可以有效地抑制p53的乳酸化。机制示意图基于癌症患者的数据，研究人员还发现，在许多肿瘤类型中AARS1的表达水平都升高，并且与p53乳酸化水平升高、p53活性降低、以及野生型p53患者的生存率较差相关。在研究的最后，周芳芳团队还测试了β-丙氨酸的抗癌潜力。她们发现，β-丙氨酸处理可适度抑制肿瘤细胞增殖、克隆形成和异种移植瘤的生长。值得注意的是，β-丙氨酸可以增强化疗药物多柔比星（DOX）在肿瘤小鼠模型上的抗癌效果。β-丙氨酸可增强化疗效果总的来说，周芳芳团队的这项研究成果表明，肿瘤产生的乳酸会通过乳酸化作用拮抗p53的抑癌功能，并揭示了AARS1是p53乳酸化的关键酶，以及β-丙氨酸可以阻止p53的乳酸化。这一机制的发现，让我们对肿瘤的糖酵解代谢有了新认知，也为癌症的治疗提供了新思路。参考文献：[1].Zong et al., Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis, Cell. 2024. doi:10.1016/j.cell.2024.04.002[2].https://ibms.suda.edu.cn/aa/81/c3463a567937/page.htm本文作者丨BioTalker

临床1期

2024-01-24

·奇点网

碳酸锂立功，把这句话念叨几遍。

*仅供医学专业人士阅读参考最近奇点糕给日常锻炼又上了点强度，结果就是身体酸痛各种如影随形，不用说，乳酸这位“老朋友”又来“做贡献”了。虽说很多研究已经显示，乳酸并不是运动后肌肉酸痛的唯一原因，但肯定有不少读者跟奇点糕一样，第一时间想到的还是乳酸吧。但在人体内，还有一个更要命的乳酸生成源头——癌细胞，它们产生乳酸的能力可达正常细胞的40倍，是癌细胞重要的能量来源，而肿瘤微环境也因此堆积着大量乳酸，癌细胞还会通过乳酸抑制T细胞功能，所以某种程度上说，乳酸也算一个癌症免疫“代谢检查点”[1-2]。那么有没有什么方法，把这些乳酸变废为宝，助力癌症治疗呢？今天，华中科技大学同济医学院/中国医学科学院基础医学研究所黄波团队就在Nature Immunology期刊发表了最新研究成果，通过“老药新用”使肿瘤微环境中的乳酸助力抗肿瘤免疫应答，这项研究的主角更是让奇点糕吃了一惊：碳酸锂？这不是用来治疗双相情感障碍等精神类疾病的经典药物吗？该研究首次揭示，肿瘤微环境中的乳酸进入CD8+T细胞后，碳酸锂能将它们快速引导至线粒体进行氧化代谢，成为T细胞全新的能量来源，从而有效激活CD8+T细胞，并逆转乳酸过度堆积导致的CD8+T细胞功能抑制，这有望使碳酸锂成为癌症免疫治疗的好搭档[3]。论文首页截图虽说此前就有研究显示，注射乳酸钠溶液能增强小鼠体内的CD8+T细胞干性，使它们更好地发挥抑癌作用，但这个套路顶多能在体外扩增T细胞和培养，比如制备CAR-T疗法的时候派上用场[4]，总不能直接给人类患者注射乳酸钠吧？还好，黄波团队注意到了2017年分析碳酸锂抗抑郁机制的一项研究，研究中碳酸锂能够降低患者大脑内的乳酸盐水平[5]。以此为切入点，黄波团队开始分析碳酸锂对CD8+T细胞内乳酸代谢的影响，借助同位素示踪技术，研究者们证实碳酸锂处理并不会抑制CD8+T细胞摄取细胞外的乳酸，因此碳酸锂更可能改变的是乳酸的分布和代谢路径；在碳酸锂处理后，被同位素标记的乳酸会在CD8+效应T细胞的线粒体积聚，使线粒体内的乳酸水平升高了近5倍（2.91% vs. 14.39%）。而用碳酸钠、氯化钠来处理，都不能达到类似的效果，也不能像碳酸锂一样有效逆转CD8+T细胞受到的抑制，且碳酸锂的作用是乳酸依赖性的；同位素示踪还证实在碳酸锂处理时，乳酸被摄取到T细胞内后就被直接转运到了线粒体，没有先被转化成丙酮酸盐。碳酸锂处理可将外源性乳酸导入线粒体内接下来，研究者们逐步明确了碳酸锂调运乳酸、激活CD8+T细胞的分子机制。分析显示，碳酸锂可作用于溶酶体膜上的V-ATP质子泵，阻碍胞浆中的氢离子进入溶酶体腔内，使溶酶体PH值升高、酸化程度降低，而这会从两个方面影响乳酸在线粒体内的代谢。首先，碳酸锂改变溶酶体PH值，可使溶酶体内的酸性神经鞘磷脂酶（ASM）不再在乳酸增多时发生组蛋白赖氨酸乳酸化（Kla），ASM水平由此相应上升，产生更多作为第二信使分子的甘油二酯（DAG），DAG则会激活蛋白激酶Cθ（PKCθ），使其调控负责转运乳酸的单羧酸转运蛋白1（MCT1）线粒体靶向序列磷酸化，MCT1就不会再像平时一样进入内质网（原本存在内质网靶向序列），而是重定位至线粒体内膜，随即把大量乳酸调运而来。碳酸锂处理使MCT1进入线粒体内膜另一方面，碳酸锂对V-ATP质子泵的影响，还会使溶酶体释放更多钙离子，钙离子进而会激活转录因子TFEB，TFEB则会结合到乳酸脱氢酶B（LDHB）基因的启动子部位、上调LDHB表达，最终由LDHB承担将乳酸转化为丙酮酸盐的使命，这样就能使被大量运来的乳酸在线粒体内重新进入三羧酸循环，被有效氧化代谢，为CD8+T细胞注入新动力。碳酸锂抑癌的分子机制汇总最后，研究者们在小鼠实验中证实，碳酸锂可通过上述分子机制，有效增加CD8+T细胞向肿瘤的浸润，并增强它们的抗肿瘤免疫战斗力；与PD-1抑制剂联合使用时，碳酸锂也明确实现了协同增效，调节CD8+T细胞的能力和抑癌效果都更进一步。分析还显示，人类癌症患者胸腔积液和肿瘤组织间液中，乳酸水平与CD8+T细胞功能呈负相关，而碳酸锂处理也确实能逆转来自人体肿瘤组织中浸润性CD8+T细胞抑制状态。碳酸锂在小鼠实验中助力免疫治疗的成果总而言之，碳酸锂这个已被使用了百余年的经典精神科用药，也许就能在癌症免疫治疗时代焕发完全意想不到的新生，就像它们能给CD8+T细胞带来全新的能量来源一样，奇点糕不禁想到那句诗了，真是“柳暗花明又一村”啊。参考文献：[1] Romero-Garcia S, Moreno-Altamirano M M B, Prado-Garcia H, et al. Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance[J]. Frontiers in Immunology, 2016, 7: 52.[2] Li Z, Cui J. Targeting the lactic acid metabolic pathway for antitumor therapy[J]. Molecular Therapy-Oncolytics, 2023, 31: 100740.[3] Ma J, Tang L, Tan Y, et al. Lithium carbonate revitalizes tumor-reactive CD8+ T cells by shunting lactic acid into mitochondria[J]. Nature Immunology, 2024.[4] Feng Q, Liu Z, Yu X, et al. Lactate increases stemness of CD8+ T cells to augment anti-tumor immunity[J]. Nature communications, 2022, 13: 4981.[5] Machado-Vieira R, Zanetti M V, Otaduy M C, et al. Increased brain lactate during depressive episodes and reversal effects by lithium monotherapy in drug-naive bipolar disorder: A 3T 1H-MRS study[J]. Journal of Clinical Psychopharmacology, 2017, 37(1): 40-45.本文作者丨谭硕

免疫疗法细胞疗法

2024-01-19

·PRNewswire

Rehydrating Rose Bowl Runners: Electrolit Activates for 2024 as Official Partner of SoCal's Major Marathon Events

Electrolit kicks off LA's first marquee race of 2024 with premium hydration at the iconic Rose Bowl Half Marathon & 5k. HOUSTON, Jan. 19, 2024 /PRNewswire/ -- Electrolit – the preferred, premium hydration beverage made from pharmaceutical quality grade ingredients – returns with a new multiyear partnership with The McCourt Foundation, becoming the official hydration sponsor for some of Southern California's most iconic races. The season kicks off with the Rose Bowl Half Marathon and 5k on January 21, 2024, and includes the Los Angeles Marathon in March. "Fueling the fire at SoCal's running community – that's what Electrolit is all about," said Jake Sloan, Sr. Marketing Director. "We're pumped to be powering athletes and runners at the iconic Rose Bowl Half & 5K, and our partnership with The McCourt Foundation lets us be there every step of the way, delivering the hydration edge they need to crush their goals." The picturesque course of the Rose Bowl Half Marathon & 5K guides participants through Pasadena, highlighting landmarks such as the Colorado Street Bridge, Old Town Pasadena, and Cal Tech University. The race concludes with a finish at the iconic Rose Bowl and benefits The McCourt Foundation – a nonprofit committed to curing neurological diseases and empowering communities to foster a healthier world. Fueling both runners and athletes for instant recovery, Electrolit can also be enjoyed by everyone. Its unique formula is packed with great taste and comes in a variety of flavors including coconut, strawberry kiwi, and many more. Electrolit is the must-have hydration beverage for runners by refueling electrolytes and keeping them hydrated during heat exposure. Scientifically formulated with magnesium, sodium, potassium, calcium and glucose, Electrolit's electrolytes and ions are key to replenishing the body and revered by runners everywhere. Multiple flavor offerings including Blue Raspberry, Strawberry-Kiwi, Grape, Orange, Berry Bliss, and Fruit Punch, and new ready-to-mix powder formats with pharmaceutical quality grade ingredients, make Electrolit the go-to hydration option for runners, athletes, party-goers and everyone else in between. Electrolit can also be purchased at Walmart, Kroger, HEB, Jewel-Osco, Circle K, 7-Eleven and more, and through online channels. For more information, visit or follow them on Instagram or Facebook. About Electrolit Electrolit manufactures a scientifically formulated premium hydration beverage that replenishes the body after physical activity, intense heat, or a night of partying. Founded in Mexico in 1950, since, Electrolit has become revered by athletes and partygoers alike as a recovery drink. Formulated with magnesium, potassium, calcium, sodium glucose, and sodium lactate plus six ions for electrolyte absorption, Electrolit aids in the recovery of the hydro electrolytic imbalance, fulfilling metabolic and hydration needs. Available in 15 delicious flavors, Electrolit is currently offered in national, grocery, convenience and online channels across the nation, including Walmart, Kroger, Jewel-Osco, 7-11 and more. Electrolit is manufactured and owned by Pisa Pharmaceuticals, the largest pharmaceutical company in Mexico and Latin America. About The McCourt Foundation The McCourt Foundation (TMF) is a 501c3 organization committed to building a healthier world through research, partnerships, and education. TMF empowers individuals and communities to make a difference through its events and educational forums. Now in LA and Boston, we have expanded our giving capacity and overall impact from coast to coast. Since 1992 when the McCourt brothers organized a road race to honor their father who battled Multiple Sclerosis, TMF committed itself to enhance the lives of patients and families affected by neurological diseases (MS, ALS, Alzheimer's, and Parkinson's). From this single fund-raising event, TMF has expanded its Mission to include youth health & wellness and other health challenges, and its world-class portfolio of events to include the Los Angeles Marathon presented by ASICS, LA Big 5k, Rose Bowl Half Marathon & 5K, Santa Monica Classic 5K/10K, Boston Waterfront 5K, Tour de South Shore, the McCourt Gala & Auction, and the Educational Update. These nine community events engage more than 100,000 participants each year and are expertly leveraged by TMF to drive impact. For more information, please visit . Media Contact Matt Kovacs [email protected] SOURCE Electrolit

100 项与乳酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02183	乳酸钠	V03	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
酸碱平衡失调	美国	Baxter Healthcare Corp.	1971-03-22
电解质不平衡	日本	Otsuka Pharmaceutical Factory, Inc.	1970-01-30

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑损伤	临床3期	-	Geneva University Hospital	2024-01-01
高血压	临床3期	-	Geneva University Hospital	2024-01-01
牙齿侵蚀症	临床3期	美国	GSK Plc	2017-11-13
多处创伤	临床3期	印尼	Innogene Kalbiotech Pte Ltd.	2009-07-01
出血性休克	临床3期	印尼	Innogene Kalbiotech Pte Ltd.	2009-07-01
毛细血管渗漏综合征	临床3期	印尼	Innogene Kalbiotech Pte Ltd.	2008-05-01
休克	临床3期	印尼	Innogene Kalbiotech Pte Ltd.	2008-05-01
创伤性脑损伤	临床3期	法国	PT Kalbe Farma Tbk	2003-11-01
颅内高压	临床3期	法国	PT Kalbe Farma Tbk	2003-11-01
低心排综合征	临床3期	印尼	Innogene Kalbiotech Pte Ltd.	2002-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESC2023	N/A	-	8	Sodium lactate infusion	願壓鹹蓋選糧積鹽獵製(鑰窪繭顧淵觸鹹夢襯衊) = 憲餘窪鑰觸製鑰壓膚壓淵願遞鏇夢憲襯蓋獵鬱 (襯衊窪繭簾窪鹽壓廠糧, -2.1 ~ -0.18) 更多	-	2023-08-28
NCT01981655 (Pubmed \| Crit Care)	临床2期	急性失代偿性心力衰竭	40	Half-molar sodium lactate infusion	壓製觸糧鹽網艱窪蓋壓(壓構願觸衊繭築夢構築) = 夢糧築鏇顧衊糧廠鬱蓋鬱壓願繭顧鏇鑰願窪衊 (觸膚淵構廠簾構鹽繭糧 )	-	2014-03-25